Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma
By: Sofiane Maza, Ralph Buchert, Winfried Brenner, Dieter Ludwig Munz, Eckhard Thiel, Agnieszka Korfel and Philipp Kiewe
Open Access
|May 2013References
- 1. Kimura N, Yamamoto Y, Kameyama R, Hatakeyama T, Kawai N, Nishiyama Y. Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor.2009;602-9.
- 2. Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET).1996;337-46.
- 3. Pierce MA, Johnson MD, Maciunas RJ, Murray MJ, Allen GS, Harbison MA, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography.1995;594-8.
- 4. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.1987;360-71.
- 5. Kuwabara Y, Ichiya Y, Otsuka M, Miyake Y, Gunasekera R, Hasuo K, et al. High [18F]FDG uptake in primary cerebral lymphoma: a PET study.1988;47-8.
- 6. Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma.2008;223-8.
- 7. Mohile NA, Deangelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma.2008;818-20, 840.
- 8. Kawai N, Okubo S, Miyake K, Maeda Y, Yamamoto Y, Nishiyama Y, et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.2010;335-43.
- 9. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.2006;164-8.
- 10. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.1992;532-6.
- 11. Karantanis D, O’Eill B P, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, et al. 18F-FDG PET/CT in primary central nervous system lymphoma in HIVnegative patients.2007;834-41.
- 12. Karantanis D, O’Neill BP, Subramaniam RM, Peller PJ, Witte RJ, Mullan BP, et al. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.2007;271-4.
- 13. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.2007;78-86.
- 14. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.2005;5034-43.
- 15. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.2008;1812-20.
- 16. Korfel A, Martus P, Nowrousian MR, Hossfeld DK, Kirchen H, Brucher J, et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.2005;177-83.
Language: English
Page range: 103 - 110
Published on: May 21, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2013 Sofiane Maza, Ralph Buchert, Winfried Brenner, Dieter Ludwig Munz, Eckhard Thiel, Agnieszka Korfel, Philipp Kiewe, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.